Are the antiplatelet and profibrinolytic properties of selective serotonin-reuptake inhibitors relevant to their brain effects?

Thromb Res. 2014 Jul;134(1):11-6. doi: 10.1016/j.thromres.2014.02.028. Epub 2014 Mar 5.


The serotonin transporter (SERT) is found in neuron and platelet membranes. Selective serotonin-reuptake inhibitors (SSRIs) are widely prescribed for severe depression. They may at least partly counteract the effects of serotonin on the vascular biology system, can lower agonists-induced platelet activation, aggregation and procoagulant activity in vitro, thus modulating platelet thrombogenicity. Other effects, such as those mediated through PAI-1 modulation, may indirectly influence neurobiology-relevant mechanisms involved in depression. Patients receiving SSRIs are at increased bleeding risk and decreased risk of arterial occlusive events, such as myocardial infarction, compared to those using non-SSRI antidepressants. The objectives of this review were to highlight antiplatelet and profibrinolytic properties of SSRIs and discuss the potential role of these activities in the context of SSRI brain effects.

Keywords: Antithrombotics; Selective serotonin-reuptake inhibitors (SSRIs); Severe depression.

Publication types

  • Review

MeSH terms

  • Antidepressive Agents / pharmacology
  • Blood Platelets / drug effects*
  • Brain / drug effects*
  • Humans
  • Platelet Activation / drug effects*
  • Serotonin Uptake Inhibitors / pharmacology*


  • Antidepressive Agents
  • Serotonin Uptake Inhibitors